The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”, “Selvita”) hereby announces that the company affiliated with Selvita – Fidelta d.o.o. (“Fidelta”) with its registered office in Zagreb, Croatia has concluded on December 23, 2021 a statement of work with a total value of EUR 2.280.913 (PLN 10.574.084,57 converted at the exchange rate EUR 1=PLN 4.6359) under a framework agreement executed on 1st October 2018 between Fidelta and one of the largest pharmaceutical companies in Europe (“Client”). The aim of this collaboration is to identify a lead compound, for the treatment of asthma, including severe asthma, which is suitable for the safety assessment and a development to candidate nomination. Fidelta, in its laboratories in Zagreb, will provide services in the area of medicinal chemistry, in vitro and in vivo pharmacology, DMPK and pharmaceutical sciences.

The services under this statement of work order will be provided over the next 12 months (until December 31, 2022). The total value of the services that will be provided by Selvita Capital Group to the Client in 2022 currently amounts to EUR 3.302.448.28 (PLN 15.309.820,00 converted at the above-mentioned exchange rate).

Taking into account value of the statement of work and its scope, the Company’s Management Board considers the order to be significant for the implementation of Selvita Group’s long-term plans aiming at building a strong position as a provider of Integrated Drug Discovery services.

Legal basis: Art. 17.1 of MAR

Representatives of the Company:
• Bogusław Sieczkowski – President of the Management Board
• Mirosława Zydroń – Management Board Member